A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery

被引：52

作者：

Sutter, Jennifer A. ^{[1
,2
]}

Kwan-Morley, Jennifer ^{[3
]}

Dunham, Jon ^{[3
]}

Du, Yang-Zhu ^{[1
,2
]}

Kamoun, Malek ^{[1
,2
]}

Albert, Daniel ^{[4
]}

Eisenberg, Robert A. ^{[3
]}

Prak, Eline T. Luning ^{[1
,2
]}

机构：

[1] Univ Penn, Sch Med, Dept Pathol, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA

[2] Univ Penn, Sch Med, Lab Med, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA

[4] Dartmouth Hitchcock Med Ctr, Rheumatol Sect, Lebanon, NH 03756 USA

来源：

CLINICAL IMMUNOLOGY | 2008年 / 126卷 / 03期

关键词：

B cells; systemic lupus; erythematosus; autoimmunity; human; transitional B cells; immunophenotype;

D O I：

10.1016/j.clim.2007.11.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Identifying factors associated with B lymphocyte depletion and recovery may aid the development of individualized treatment regimens, optimizing therapy for patients with autoimmune disease. In this study, 12 patients with active SLE were monitored at baseline and monthly following treatment with rituximab. The number and phenotype of peripheral blood B lymphocytes, T lymphocytes and natural killer cells were correlated with the extent and longevity of B lymphocyte depletion. This analysis generated three candidate biomarkers for lymphocyte monitoring in patients with autoimmune disease who are treated with rituximab: circulating transitional B cells, the K: ratio and natural killer cells. Further refinement of these potential biomarkers may lead to a better understanding of the rote of B cells in disease pathogenesis and a more rational use of B cell depletion therapies. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：282 / 290

页数：9

共 30 条

[1] Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus [J].

Anolik, JH ;

Barnard, J ;

Cappione, A ;

Pugh-Bernard, AE ;

Felgar, RE ;

Looney, RJ ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3580-3590

[2] Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus [J].

Arce, E ;

Jackson, DG ;

Gill, MA ;

Bennett, LB ;

Banchereau, J ;

Pascual, V .

JOURNAL OF IMMUNOLOGY, 2001, 167 (04) :2361-2369

[3] Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab [J].

Bowles, Julie A. ;

Wang, Siao-Yi ;

Link, Brian K. ;

Allan, Barrett ;

Beuerlein, Gregory ;

Campbell, Mary-Ann ;

Marquis, David ;

Ondek, Brian ;

Wooldridge, James E. ;

Smith, Brian J. ;

Breitmeyer, James B. ;

Weiner, George J. .

BLOOD, 2006, 108 (08) :2648-2654

[4] Naive B lymphocytes undergo homeostatic proliferation in response to B cell deficit [J].

Cabatingan, MS ;

Schmidt, MR ;

Sen, R ;

Woodland, RT .

JOURNAL OF IMMUNOLOGY, 2002, 169 (12) :6795-6805

[5] Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases [J].

Chambers, SA ;

Isenberg, D .

LUPUS, 2005, 14 (03) :210-214

[6] Incomplete activation of CD4 T cells by antigen-presenting transitional immature B cells: Implications for peripheral B and T cell responsiveness [J].

Chung, JB ;

Wells, AD ;

Adler, S ;

Jacob, A ;

Turka, LA ;

Monroe, JG .

JOURNAL OF IMMUNOLOGY, 2003, 171 (04) :1758-1767

[7]

Cohen Y, 2003, HAEMATOLOGICA, V88, P811

[8] B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels [J].

Collins, CE ;

Gavin, AL ;

Migone, TS ;

Hilbert, DM ;

Nemazee, D ;

Stohl, W .

ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)

[9]

Dörner T, 2006, J RHEUMATOL, V33, P3

[10] Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus [J].

Dörner, T ;

Lipsky, P .

LUPUS, 2004, 13 (05) :283-289

← 1 2 3 →